ERVW-1 and infection: The top two panels of Figure 3A shows that treatment with IMB, NIL, and DAS decreased infection with R5 HIVYU2 virus and X4 HIVHXB2 virus by an average of 91±7%, 88±4%, and 91±5%, respectively, comparable to the reductions observed with Env-dependent cell-cell fusion, virus-dependent cell-cell fusion and virus-cell fusion (Figure 2).